Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuxi Shansheng Pharmaceutical
Wuxi, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Wuxi Shansheng Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuxi, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas including metabolic diseases, particularly hyperuricemia and gout, as well as autoimmune disorders. Its lead candidate, SS-101, is a potent URAT1 inhibitor currently in clinical development for the treatment of chronic gout. Shansheng leverages its internal R&D capabilities to advance a pipeline of targeted therapies aimed at addressing significant unmet medical needs in the Chinese and global markets.
- Therapeutic areas
- Metabolic DisordersRheumatologyDermatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Wuxi Shansheng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuxi Shansheng Pharmaceutical.